Table 1.
Baseline clinical characteristics of AML patients analyzed in this study.
| Characteristic | Treatment-naive at enrollment, no. (%) | Previously treated and relapsed at enrollment, no. (%) |
|---|---|---|
| Sample size (95 total) | 76 (79) | 19 (21) |
| Age, y | ||
| Median | 64 | 65 |
| Range | 20–85 | 21–79 |
| Sex | ||
| Male | 45 (59) | 11 (58) |
| Female | 31 (41) | 8 (42) |
| FAB classification* | ||
| M0 | 10 (16) | 0 (0) |
| M1 | 13 (20) | 3 (20) |
| M2 | 12 (19) | 3 (20) |
| M4 | 24 (37) | 6 (40) |
| M5 | 5 (8) | 3 (20) |
| M6 | 0 (0) | 0 (0) |
| M7 | 0 (0) | 0 (0) |
| Immunophenotype | ||
| CD13 positive | 67 (88) | 16 (84) |
| CD33 positive | 66 (87) | 19 (100) |
| CD34 positive | 60 (79) | 10 (53) |
| CD117 positive | 70 (92) | 17 (89) |
| Cytogenetic class** | ||
| Favorable | 6 (8) | 0 (0) |
| Intermediate | 38 (51) | 16 (84) |
| Unfavorable | 31 (41) | 3 (16) |
| No. of karyotypic abnormalities | ||
| Three or more | 16 (20) | 1 (5) |
| Less than three | 59 (80) | 18 (95) |
| Pathogenesis | ||
| De novo | 51 (67) | 15 (78) |
| Prior myelodysplasia | 10 (13) | 2 (11) |
| Treatment-related | 15 (20) | 2 (11) |
*
The FAB subclassification was unspecified in 16 samples. The M3 subtype was not included in this study.
**
One sample had no cytogenetic data available